secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0000950170-23-013199
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RLY-2608 shows selective PI3Kα inhibition, no Grade 3 hyperglycemia, partial response in breast cancer
--------------------------------------------------------------------------------

- No Grade 3 hyperglycemia, rash, or diarrhea at target exposures; no dose-limiting toxicities or discontinuations.
- Confirmed partial response (RECIST) in metastatic HR+/HER2- breast cancer patient with 12 prior lines of therapy.
- Target exposure (~80%+ mutant PI3Kα inhibition) achieved at 400mg BID monotherapy and 600/800mg BID combination.
- Nine of 16 breast cancer patients with measurable disease had radiographic tumor reductions; 11 remain on treatment.
- Expansion cohorts expected in H2 2023; new first-in-human trial for second PI3Kα inhibitor RLY-5836 initiated April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023013199/0000950170-23-013199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023013199/rlay-20230418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer